Literature DB >> 8250576

Chronic cutaneous lupus erythematosus treated with thalidomide.

A L Holm1, K E Bowers, T O McMeekin, A A Gaspari.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8250576

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


× No keyword cloud information.
  6 in total

1.  Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn's disease.

Authors:  J Bauditz; S Wedel; H Lochs
Journal:  Gut       Date:  2002-02       Impact factor: 23.059

Review 2.  Lupus therapy.

Authors:  H Baart de la Faille
Journal:  Clin Investig       Date:  1994-10

3.  Thalidomide inhibits adipogenesis of orbital fibroblasts in Graves' ophthalmopathy.

Authors:  Chu Zhang; Xianfeng Zhang; Lizhen Ma; Fengying Peng; Jiao Huang; Hui Han
Journal:  Endocrine       Date:  2012-01-12       Impact factor: 3.633

4.  Lenalidomide for the treatment of resistant discoid lupus erythematosus.

Authors:  Asha Shah; Joerg Albrecht; Zuleika Bonilla-Martinez; Joyce Okawa; Mathew Rose; Misha Rosenbach; Victoria P Werth
Journal:  Arch Dermatol       Date:  2009-03

Review 5.  [Dermatological symptoms in rheumatology].

Authors:  E Aberer
Journal:  Z Rheumatol       Date:  2008-09       Impact factor: 1.372

6.  Therapeutic and prophylactic thalidomide in TNBS-induced colitis: synergistic effects on TNF-alpha, IL-12 and VEGF production.

Authors:  Ana Teresa Carvalho; Heitor Souza; Antonio Jose Carneiro; Morgana Castelo-Branco; Kalil Madi; Alberto Schanaider; Flavia Silv; Fernando Antonio Pereira Junior; Marcia G Pereira; Claudio Tortori; Ilana Dines; Jane Carvalho; Eduardo Rocha; Celeste Elia
Journal:  World J Gastroenterol       Date:  2007-04-21       Impact factor: 5.742

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.